SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples post-earnings decline is centered on guidance for weaker gross margins as memory costs rise, despite stronger-than-expected quarterly results. Traders are split between viewing the drop as an overreaction to a solid iPhone-led quarter and worrying that margin pressure, slower growth, and valuation leave little room for disappointment.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs quarterly report is in focus after Intels weak outlook helped trigger a broader semiconductor selloff and weighed on AMD shares. Traders are divided over whether AI and data-center growth and strong guidance can reassure investors, or whether valuation concerns and cautious chip-sector sentiment will overshadow the results.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 trial reaching its prespecified 80th event has triggered final analysis, with traders focused on the pending GPS topline results and a possible SLS009 update. The sharp selloff has prompted some investors to buy or hold ahead of the data, while others see the decline as a warning of possible trial weakness; claims of manipulation, dilution, or leaked results remain speculation.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs strong Q3 results and raised outlook drew attention, but shares fell as traders questioned whether rapid growth could justify the stocks high valuation. Bulls pointed to accelerating commercial AI adoption, while bears focused on lofty expectations and slower growth in contract value.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles planned stock-and-bond financing for its AI infrastructure buildout is driving the selloff, with traders focused on shareholder dilution, rising debt and whether the spending will generate returns. Some argue the financing was previously outlined and could limit future fundraising, while others see its timing as a warning about Oracles leverage and AI investment risks.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

SLV is drawing attention amid a steep silver-price selloff after a dramatic run-up, with traders reacting to persistent declines and questioning where support may hold. The community is split between bearish calls for further losses and dip buyers expecting an oversold rebound; some blame rate and yield pressures or technical selling, while claims of market manipulation remain speculation.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A strong fiscal Q1 report and raised FY27 outlook, supported by demand for Aehrs AI-chip burn-in testing systems, are driving attention. Bulls see the results as evidence of growth, while others question the stocks valuation and worry that broader market weakness could blunt the reaction.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDBs CEO departure to Meta, announced immediately before Investor Day, sparked a sharp selloff and volatile trading. Traders are split between viewing the leadership uncertainty as a lasting risk and seeing the drop as an overreaction, pointing to reaffirmed guidance and former CEO Dev Ittycherias return as interim chief.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,883,313.16514313 with 590,206,315.78603745 in circulation. The last known price of Solana is 92.37097662 USD and is down -1.79 over the last 24 hours. It is currently trading on 1189 active market(s) with $2,843,805,655.98 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solanas slide amid broader crypto weakness is driving discussion, with traders watching technical support and warning of further downside. Others view the pullback as a buying opportunity and say they are accumulating and staking, leaving sentiment divided.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA accelerated approval of Inovios competing RRP treatment has intensified concerns about competition for Precigens PAPZIMEOS and accompanied a sharp selloff. Traders debate whether the rivals dosing regimen will draw patients away or whether PAPZIMEOSs commercial head start, full approval, and reported efficacy will help it retain an advantage.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -42.86% and -1.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

PHAT Stock Eyes Worst Day In Nearly Two Years After Generic Drug Maker Challenges Key Drug’s Exclusivity

Equity

Phathom said BDR Pharmaceuticals International Pvt. Ltd. filed suit in the U.S. District Court for the District of Columbia against the FDA and related federal defendants.


Phathom Says BDR Pharmaceuticals Sues FDA Over VOQUEZNA Exclusivity

(RTTNews) - Biopharmaceutical company Phathom Pharmaceuticals, Inc. (PHAT) announced on Friday that Mumbai, India-based BDR Pharmaceuticals International Pvt. Ltd. has filed a lawsuit against the U.S. Food and Drug Administration or FDA, challenging the agency's decision to grant...

PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. (Phathom or the Company) (NASDAQ: PHAT) for violations of the securities laws. INVESTIGATION DETAILS: The...

PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival 

Leerink said that VOQUEZNA competes in a “highly genericized” gastroesophageal reflux disease market against long-available proton pump inhibitors (PPI). 


PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses after the Company lowered its full-year 2026 revenue guidance to $310 million$325 million from its previously issued $320 million$345 million range, falling below Wall Street consensus estimates of approximately $332 million. If...

PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals

PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals PR Newswire NEW YORK, July 31, 2026 Phathom...

PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?

Phathom lowered its full-year 2026 net revenue outlook to $310–325 million from the prior $320–345 million range.


Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT) Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT) PR Newswire...

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of $0.04 up 126.67% YoY
• Reported revenue of $84.72M up 71.15% YoY

Phathom Pharmaceuticals faces exclusivity litigation, a $387.5M revenue-interest financing liability with no further funding available, and customer concentration, as three customers accounted for 67% of Q3 product sales.

Phathom Pharmaceuticals reported higher Q3 product revenue, more than 2M prescriptions filled with broad commercial access, and advancing EoE and as-needed NERD clinical programs.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Bullish Sentiment

<ul class="summary-bullets"><li>BDR is principally challenging the FDA’s alleged refusal to accept an abbreviated new drug application referencing Phathom’s new drug application for VOQUEZNA tablets.&nbsp;</li><li>Phathom said it is reviewing BDR’s filings but believes the FDA carefully and correctly evaluated the issue when it recognized the drug’s exclusivity until 2032.&nbsp;</li><li>The company stated it “intends to take appropriate action to protect its statutory exclusivities.”</li></ul>Shares of Phathom Pharmaceuticals (PHAT) plunged roughly 23% on Friday after the company disclosed that BDR Pharmaceuticals had sued the U.S. Food and Drug Administration over exclusivity for its key drug VOQUEZNA.Phathom said BDR Pharmaceuticals International Pvt. Ltd. filed suit in the U.S. District Court for the District of Columbia against the FDA and related federal defendants. BDR is principally challenging the FDA’s alleged refusal to accept an abbreviated new drug application (ANDA)—the pathway for a generic version—referencing Phathom’s new drug application for VOQUEZNA tablets.BDR claims the FDA improperly applied laws to extend Phathom’s drug’s exclusivity. The stock is now on track for its worst day since November 2024, if the losses hold.<h2 class="st-heading-2">VOQUEZNA Market And Exclusivity</h2>VOQUEZNA is used for heartburn related to non-erosive gastroesophageal reflux disease (GERD), healing and maintenance of erosive GERD, and as a combination for H. pylori infection. The drug was first approved in May 2022 and later for other indications. The drug carries 10 years of exclusivity and protection against generic versions, until May 2032.Phathom said it is reviewing BDR’s filings but believes the FDA carefully and correctly evaluated the issue when it recognized the drug’s exclusivity until 2032. The company stated it “intends to take appropriate action to protect its statutory exclusivities.” An adverse outcome could shorten exclusivity, allow earlier ANDA acceptance and potential approval, and pressure VOQUEZNA sales, the stock price, and overall business prospects.<h2 class="st-heading-2">Wall Street Weighs In On PHAT</h2>Cantor Fitzgerald acknowledged that ongoing lawsuits can create overhangs for stocks. However, the firm sees a low likelihood that the FDA will reverse its decision and estimates Phathom still has more than six years of selling VOQUEZNA without competition. Cantor maintained its ‘Overweight’ rating on the shares.Phathom Pharmaceuticals reported $175.1 million in net revenue for full-year 2025. This was a 217% increase from $55.3 million in 2024, and essentially all came from sales of its VOQUEZNA franchise.<h2 class="st-heading-2">How Did PHAT Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$PHAT" data-symbol-id="PHAT" href="https://stocktwits.com/symbol/PHAT" target="_blank">PHAT stock</a> jumped from 'bearish' to 'extremely bullish' territory over the past 24 hours, while message volume rose from 'low' to 'extremely high' levels.A Stocktwits user highlighted that the lawsuit is not confirmation of generic competition.<stembedurl>https://stocktwits.com/Mungermind/message/667242289</stembedurl>Another user said that the lawsuit will have little impact besides causing the selloff, as the FDA will not allow generics for the drug.<stembedurl>https://stocktwits.com/Canvasback33/message/667239660</stembedurl><a href="https://stocktwits.com/symbol/PHAT">PHAT stock </a>has dropped 67% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/iovance-s-melanoma-therapy-shows-promising-4-year-data-retail-says-acquisition-imminent-before-2027-end/cZxyVmpRBxw">Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the Phathom Pharmaceuticals' logo is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Phathom said BDR Pharmaceuticals International Pvt. Ltd. filed suit in the U.S. District Court for the District of Columbia against the FDA and related federal defendants.

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$5.92
Prev Close	$5.74
Open	$5.76
Dividend Yield	0.00%
50-Day Moving Average	$7.58
Beta	1.10
Avg. Volume	1.68M
PE Ratio	-5.74

52-Week High	$18.31
52-Week Low	$5.02
Market Capitalization	$466.61M
EPS (Annual)	-$3.03
Price to Book	-1.38
Revenue Per Employee	$471,994.61

Feed

News

Sentiment

Earnings

Fundamentals

Info

PHAT Fundamentals